Wan Chi-Dan, Cheng Rui, Wang Hong-Bo, Liu Tao
Department of General Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Hepatobiliary Pancreat Dis Int. 2008 Feb;7(1):29-33.
Acute rejection after liver transplantation is usually treated with large doses of immunosuppressants with severe toxic and side-effects, so it is imperative to find a safe and effective method for preventing and treating rejection. This study was designed to confirm the immunomodulatory effects of rat mesenchymal stem cells (MSCs) in vitro and investigate the tolerogenic features in a rat model of allogeneic liver transplantation.
MSCs were isolated from adipose tissue of Sprague-Dawley (SD) rats and cultured. In vitro, MSCs were added into a mixed lymphocyte culture (MLC) system to study the inhibitory effects of MSCs on the proliferation of T lymphocytes in Wistar rats. By using SD and Wistar rats as liver donors and recipients, an orthotopic liver transplantation model was established and the rats were divided into a MSC-treated group and a blank control group. On postoperative day 7, all rats were sacrificed, and the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), interleukin-2 (IL-2) and interleukin-10 (IL-10) were measured. The pathological changes of liver tissue and apoptosis of hepatocytes were also assessed.
In in vitro MLC, T lymphocyte proliferation in Wistar rats was significantly inhibited by 48.44%. In the MSC-treated group, the levels of ALT, AST, TBIL, IL-2 and IL-10 were 134.2+/-45.0 U/L, 162.5+/-30.5 U/L, 30.6+/-5.4 micromol/L, 187.35+/-18.26 microg/L and 193.95+/-37.62 microg/L, and those in the blank control group were 355.6+/-54.3 U/L, 296.4+/-71.2 U/L, 145.7+/-28.6 micromol/L, 295.73+/-57.15 microg/L and 75.12+/-11.23 microg/L, respectively, with statistically significant differences (P<0.05). Pathological examination revealed that the rejection in the MSC-treated group was clearly alleviated compared with that in the blank control group. TUNEL indicated that the apoptosis of hepatocytes in the MSC-treated group was milder than that in the blank control group (P<0.05).
Adipose-derived MSCs clearly inhibit recipient-derived T lymphocyte proliferation in MLC and significantly alleviate acute rejection following orthotopic liver transplantation in rats.
肝移植术后急性排斥反应通常采用大剂量免疫抑制剂治疗,其毒副作用严重,因此寻找一种安全有效的防治排斥反应的方法势在必行。本研究旨在证实大鼠间充质干细胞(MSCs)的体外免疫调节作用,并研究其在大鼠同种异体肝移植模型中的致耐受特性。
从Sprague-Dawley(SD)大鼠脂肪组织中分离并培养MSCs。体外实验中,将MSCs加入混合淋巴细胞培养(MLC)体系,研究其对Wistar大鼠T淋巴细胞增殖的抑制作用。以SD大鼠和Wistar大鼠分别作为供肝和受体,建立原位肝移植模型,并将大鼠分为MSCs治疗组和空白对照组。术后第7天,处死所有大鼠,检测丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBIL)、白细胞介素-2(IL-2)和白细胞介素-10(IL-10)水平。同时评估肝组织病理变化及肝细胞凋亡情况。
体外MLC实验中,Wistar大鼠T淋巴细胞增殖受到显著抑制,抑制率为48.44%。MSCs治疗组中,ALT、AST、TBIL、IL-2和IL-10水平分别为134.2±45.0 U/L、162.5±30.5 U/L、30.6±5.4 μmol/L、187.35±18.26 μg/L和193.95±37.62 μg/L;空白对照组中上述指标分别为355.6±54.3 U/L、296.4±71.2 U/L、145.7±28.6 μmol/L、295.73±57.15 μg/L和75.12±11.23 μg/L,差异具有统计学意义(P<0.05)。病理检查显示,与空白对照组相比,MSCs治疗组的排斥反应明显减轻。TUNEL检测表明,MSCs治疗组肝细胞凋亡程度较空白对照组轻(P<0.05)。
脂肪来源的MSCs在MLC中能明显抑制受体来源的T淋巴细胞增殖,并显著减轻大鼠原位肝移植后的急性排斥反应。